Grundläggande statistik
| LEI | 549300BWJLIT2S349463 |
| CIK | 1610853 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Solana Company
SEC Filings (Chronological Order)
Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.
| May 29, 2026 |
Up to $250,000,000 of Class A Common Stock TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-290429 PROSPECTUS SUPPLEMENT (To Prospectus Dated March 31, 2026) Up to $250,000,000 of Class A Common Stock We have previously entered into a sales agreement with Clear Street LLC (“Clear Street”) and Maxim Group LLC (“Maxim,” and together with Clear Street, the “Sales Agents”) dated September 15, 2025 (the “Prior Sales Agr |
|
| May 29, 2026 |
Exhibit 10.1 Solana Company Class A Common Stock ($0.001 par value per share) Amended and Restated Sales Agreement May 29, 2026 Clear Street LLC 4 World Trade Center 150 Greenwich Street, 45th Floor New York, NY 10007 Maxim Group LLC 300 Park Avenue, 16th Floor New York, NY 10022 Ladies and Gentlemen: Solana Company, a Delaware corporation (f/k/a Helius Medical Technologies, Inc.) (the “Comp |
|
| May 29, 2026 |
Solana Company Conflict Minerals Report For Calendar Year 2025 Exhibit 1.01 Solana Company Conflict Minerals Report For Calendar Year 2025 Solana Company (the “Company,” “we” and “our”) submits this Conflict Minerals Report (this “Report”) for the period January 1 to December 31, 2025 (the “Reporting Period”), pursuant to Rule 13p-1 under the Securities Exchange Act of 1934, as amended (the “Rule”). The Rule was adopted by the Securities and Exchange Commissi |
|
| May 29, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report SOLANA COMPANY (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38445 (Commission file number) 1650 Market Street, Suite 3600, PMB 17139084 Philadelphia, PA (Address of principal executive offices) 19103 (Zip Code) Joseph Ch |
|
| May 29, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2026 SOLANA COMPANY (Exact name of registrant as specified in its charter) Delaware 001-38445 36-4787690 (State or other jurisdiction (Commission File Number) (IRS Employer of |
|
| May 22, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2026 SOLANA COMPANY (Exact name of registrant as specified in its charter) - Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| May 18, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| May 15, 2026 |
SEPARATION AGREEMENT AND RELEASE Exhibit 10.3 SEPARATION AGREEMENT AND RELEASE This Separation Agreement and Release (“Agreement”) is made by and between Dane C. Andreeff (“Employee”) and Solana Company, f/k/a Helius Medical Technologies, Inc. including all subsidiaries and affiliates (the “Company”) (collectively referred to as the “Parties” or individually referred to as a “Party”). RECITALS WHEREAS, Employee has been employed |
|
| May 15, 2026 |
Exhibit 99.1 Solana Company Reports First Quarter 2026 Financial Results NEWTOWN, Pa., May 15, 2026 (GLOBE NEWSWIRE) - Solana Company (NASDAQ: HSDT) (the “Company” or “HSDT”), a publicly listed company, today announced results for the quarter ended March 31, 2026. First Quarter Recent Business Updates ● Generated $3.6 million in revenue in the first quarter of 2026, with the increase primarily dri |
|
| May 15, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-38445 SOLANA |
|
| May 15, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2026 SOLANA COMPANY (Exact name of registrant as specified in its charter) - Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| May 15, 2026 |
SEPARATION AGREEMENT AND RELEASE Exhibit 10.4 SEPARATION AGREEMENT AND RELEASE This Separation Agreement and Release (“Agreement”) is made by and between Jeffrey S. Mathiesen (“Employee”) and Solana Company, f/k/a Helius Medical Technologies, Inc. including all subsidiaries and affiliates (the “Company”) (collectively referred to as the “Parties” or individually referred to as a “Party”). RECITALS WHEREAS, Employee has been emplo |
|
| May 1, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ De |
|
| April 27, 2026 |
Exhibit 99.1 FOR IMMEDIATE RELEASE SOLANA COMPANY - HSDT Solana Company (NASDAQ: HSDT) Announces Registered Direct Offering of Common Stock to Global Institutional Investor Newtown, PA, April 27, 2026 – Solana Company (NASDAQ: HSDT) (“HSDT” or the “Company”), a publicly listed company that has expanded its business to include a digital asset treasury dedicated to acquiring and holding Solana token |
|
| April 27, 2026 |
3,076,922 Shares Class A Common Stock TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-290429 PROSPECTUS SUPPLEMENT (To Prospectus dated March 31, 2026) 3,076,922 Shares Class A Common Stock We are offering to purchasers 3,076,922 shares of our Class A common stock, par value $0.001 per share, at a purchase price of $2.60 per share, in a registered direct offering. Our Class A common stock is listed on The Nas |
|
| April 27, 2026 |
EXHIBIT 4.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of , 2026, between Solana Company, a Delaware corporation (the “Company”) and the purchaser identified on the signature page hereto (including its successors and assigns, the “Purchaser”). WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an effective r |
|
| April 27, 2026 |
solana company Put Option Agreement Exhibit 4.2 THE PUT OPTION HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF ANY STATES IN THE UNITED STATES. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE ACT AND THE APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXEMPTION |
|
| April 27, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2026 SOLANA COMPANY (Exact name of registrant as specified in its charter) Delaware 001-38445 36-4787690 (State or other jurisdiction (Commission File Number) (IRS Employer |
|
| April 24, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2026 SOLANA COMPANY (Exact name of registrant as specified in its charter) - Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| April 14, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the Fiscal Year Ended December 31, 2025 or ☐ ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File No. 001-38445 SOLANA COMPANY (Exact n |
|
| April 13, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2026 SOLANA COMPANY (Exact name of registrant as specified in its charter) - Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporation) (Commission File Num |
|
| April 13, 2026 |
SEPARATION AGREEMENT AND RELEASE EXHIBIT 10.1 SEPARATION AGREEMENT AND RELEASE This Separation Agreement and Release (“Agreement”) is made by and between Antonella Favit-Van Pelt (“Employee”) and Solana Company, f/k/a Helius Medical Technologies, Inc. (the “Company”) (collectively referred to as the “Parties” or individually referred to as a “Party”). RECITALS WHEREAS, Employee was employed by the Company; WHEREAS, Employee signe |
|
| April 10, 2026 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rul |
|
| April 9, 2026 |
Exhibit 99.1 FOR IMMEDIATE RELEASE SOLANA COMPANY – HSDT Solana Company (NASDAQ: HSDT) Appoints Madelene Gani as Chief Operating Officer and Deputy CFO to Lead Next Phase of Growth A veteran architect of Gemini’s Asia Pacific expansion, Ms. Gani joins to lead institutional buildout as Solana Company executes on its strategy to drive yield expansion, enhance revenue generation, advance business div |
|
| April 9, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 9, 2026 SOLANA COMPANY (Exact name of registrant as specified in its charter) - Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporation) (Commission File Num |
|
| April 9, 2026 |
ACKNOWLEDGEMENT AND ACCEPTANCE Exhibit 10.1 March 13, 2026 Agustina Gani Tjandrasuwita Dear Madelene: We are pleased to offer you employment with Solana Company a Delaware corporation (the “Company”). The terms of your offer are as follows: Your initial position with the Company will be Chief Operating Officer & Deputy CFO, reporting to the Executive Chairman of the Company or such other person as designed from time to time by |
|
| March 31, 2026 |
As filed with the Securities and Exchange Commission on March 31, 2026 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on March 31, 2026 Registration No. |
|
| March 31, 2026 |
Exhibit 4.3 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following summary of the terms of our capital stock is qualified in its entirety by reference to our certificate of incorporation, as amended (“Certificate of Incorporation”) and amended and restated bylaws (“Bylaws”), copies of which are filed as exhibits to our Annu |
|
| March 31, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the Fiscal Year Ended December 31, 2025 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File No. 001-38445 SOLANA CO |
|
| March 31, 2026 |
Exhibit 10.13.4 Amendment 3 to 2022 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: September 25, 2026 APPROVED BY THE STOCKHOLDERS: October 30, 2026 RECITALS A. Helius Medical Technologies, Inc., a Delaware corporation (the “Company”) sponsors the Helius Medical Technologies, Inc. 2022 Equity Incentive Plan, as amended (the “Plan”). B. The Plan is amended by this Amendment 3 (this “Third |
|
| March 31, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2026 SOLANA COMPANY (Exact name of registrant as specified in its charter) - Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| March 31, 2026 |
Solana Company Reports Fourth Quarter and Full Year 2025 Financial Results EXHIBIT 99.1 Solana Company Reports Fourth Quarter and Full Year 2025 Financial Results NEWTOWN, Pa., March 30, 2026 (GLOBE NEWSWIRE) - Solana Company (NASDAQ: HSDT) (the “Company” or “HSDT”), a publicly listed company that has expanded its business to include a digital asset treasury (“DAT”) dedicated to acquiring and holding Solana tokens (“SOL”), today announced results for the quarter and full |
|
| March 31, 2026 |
As filed with the Securities and Exchange Commission on March 31, 2026 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on March 31, 2026 Registration No. |
|
| March 31, 2026 |
SUBSIDIARIES OF SOLANA COMPANY Exhibit 21.1 SUBSIDIARIES OF SOLANA COMPANY ENTITY NAME JURISDICTION Marvel Operations Corp. Delaware Solana Company (Hong Kong) Limited Hong Kong Helius Medical, Inc. Delaware Revelation Neuro, Inc. Texas Helius Medical Technologies (Canada), Inc. Canada |
|
| March 31, 2026 |
Table 1: Newly Registered Securities Calculation of Filing Fee Tables S-8 Solana Co Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Class A common stock, par value $0. |
|
| March 31, 2026 |
As filed with the Securities and Exchange Commission on March 31, 2026 As filed with the Securities and Exchange Commission on March 31, 2026 Registration No. |
|
| March 30, 2026 |
As filed with the Securities and Exchange Commission on March 30, 2026 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on March 30, 2026 Registration No. |
|
| March 30, 2026 |
Calculation of Filing Fee Tables S-3 Solana Co Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Newly Registered Securities Equity Class A Common Stock, $0. |
|
| March 30, 2026 |
As filed with the Securities and Exchange Commission on March 30, 2026 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on March 30, 2026 Registration No. |
|
| February 20, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2026 SOLANA COMPANY (Exact name of registrant as specified in its charter) - Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporation) (Commission File |
|
| November 18, 2025 |
As filed with the Securities and Exchange Commission on November 17, 2025 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on November 17, 2025 Registration No. |
|
| November 18, 2025 |
Calculation of Filing Fee Tables S-3 Solana Co Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to be Paid 1 Equity Common Stock, par value $0. |
|
| November 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-38445 SO |
|
| November 18, 2025 |
Solana Company Reports Third Quarter 2025 Financial Results Exhibit 99.1 Solana Company Reports Third Quarter 2025 Financial Results NEWTOWN, Pa., Nov. 18, 2025 (GLOBE NEWSWIRE) - Solana Company (NASDAQ: HSDT) (the “Company” or “HSDT”), a publicly listed company that has expanded its business to include a digital asset treasury (“DAT”) dedicated to acquiring and holding Solana tokens (“SOL”), today announced results for the quarter ended September 30, 2025 |
|
| November 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2025 SOLANA COMPANY (Exact name of registrant as specified in its charter) - Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporation) (Commission File |
|
| November 17, 2025 |
Filed pursuant to Rule 424(b)(7) Registration No. 333-290950 Prospectus Supplement No. 1 (To Prospectus dated October 20, 2025) SOLANA COMPANY 37,679,950 Shares of Common Stock 36,261,239 Shares of Common Stock Underlying Pre-Funded Warrants 81,335,308 Shares of Common Stock Underlying Warrants This Prospectus Supplement No. 1 (this “Supplement”) is being filed solely to update the information con |
|
| November 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number 001-42612 CUSIP Number: G2868C 101 (Check One): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-CEN ¨ Form N-CSR For Period Ended: September 30, 2025 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Report on Form 10-Q For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. |
|
| November 5, 2025 |
Exhibit 99.1 October 30, 2025 VIA EMAIL Joseph Chee, Executive Chairman [email protected] Solana Company Dear Joseph: I hereby submit my resignation from the Board of Directors of Solana Company effective October 30, 2025. Sincerely, /s/ Jeffrey S. Mathiesen Jeffrey S. Mathiesen |
|
| November 5, 2025 |
Solana Company (NASDAQ: HSDT) Releases Investor Update Exhibit 99.2 Solana Company (NASDAQ: HSDT) Releases Investor Update NEWTOWN, Pa., Nov. 05, 2025 (GLOBE NEWSWIRE) – Solana Company (NASDAQ: HSDT) (the “Company” or “HSDT”), a publicly listed company that has expanded its business to include a digital asset treasury dedicated to acquiring and holding Solana (SOL), today announced that its Board of Directors has approved a stock repurchase program to |
|
| November 5, 2025 |
ANNEX TO THE EMPLOYMENT AGREEMENT EMPLOYEE COLLECTION STATEMENT Exhibit 10.1 Employment Agreement Dated Chee Choon Wee (the “Employee”) AND Solana Company (Hong Kong) Limited (the “Company”) Contents 目錄 Details 1 General terms1 1 Definitions and interpretation2 2 Employment2 3 Duties of the Employee3 4 Remuneration and benefits3 5 Working hours4 6 Leave5 7 Warranties and indemnities5 8 Conflict of interest6 9 Exclusivity of employment6 10 Confidentia |
|
| November 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2025 SOLANA COMPANY (Exact name of registrant as specified in its charter) - Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporation) (Commission File |
|
| November 3, 2025 |
Solana Company (NASDAQ: HSDT) Releases Investor Update Exhibit 99.2 Solana Company (NASDAQ: HSDT) Releases Investor Update NEWTOWN, Pa., Nov. 3, 2025 – Solana Company (NASDAQ: HSDT) (the “Company” or “HSDT”), a publicly listed digital asset treasury dedicated to acquiring and holding Solana (SOL), today announced the release of its latest corporate presentation (the “Investor Update”) and the election of Cosmo Jiang, General Partner at Pantera Capital |
|
| November 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2025 SOLANA COMPANY (Exact name of registrant as specified in its charter) - Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporation) (Commission File |
|
| November 3, 2025 |
Exhibit 99.1 x Investor Presentation November 2025 Exhibit 99.1 x 2 Disclaimer This presentation has been prepared by Solana Company (the “Company”) solely for information purposes. The information contained in this presentation has been prepared solely to assist interested parties in making their own evaluation with respect to the proposed transaction involving the Company and for no other purpos |
|
| October 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2025 SOLANA COMPANY (Exact name of registrant as specified in its charter) - Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporation) (Commission File |
|
| October 29, 2025 |
Solana Company Announces Updated SOL Holdings and Industry Leading Staking Yield Exhibit 99.1 Solana Company Announces Updated SOL Holdings and Industry Leading Staking Yield NEWTOWN, Pa., Oct. 29, 2025 (GLOBE NEWSWIRE) – Solana Company (NASDAQ: HSDT) (the “Company” or “HSDT) today announced its updated Solana (“SOL”) token and cash holdings as of Oct. 29 at 12:00 am ET, as well as its current staking performance. This update reflects the Company’s continued execution of its m |
|
| October 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2025 SOLANA COMPANY (Exact name of registrant as specified in its charter) - Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporation) (Commission File |
|
| October 21, 2025 |
Solana Company Executive Chairman’s Message: October 20th, 2025 Exhibit 99.1 Solana Company Executive Chairman’s Message: October 20th, 2025 NEWTOWN, Pa., Oct. 20, 2025 (GLOBE NEWSWIRE) – Today, Solana Company (NASDAQ: HSDT) released the following letter from the Executive Chairman: We are excited to enter the next phase of our lifecycle with a strong capital base and expanded accessibility for investors. This week will be remembered as a foundational moment f |
|
| October 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 20, 2025 SOLANA COMPANY (Exact name of registrant as specified in its charter) - Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporation) (Commission File |
|
| October 20, 2025 |
Calculation of Filing Fee Tables S-3 Solana Co Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to be Paid 1 Equity Common Stock, par value $0. |
|
| October 20, 2025 |
As filed with the Securities and Exchange Commission on October 17, 2025 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on October 17, 2025 Registration No. |
|
| October 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 15, 2025 SOLANA COMPANY (Exact name of registrant as specified in its charter) - Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporation) (Commission File |
|
| October 16, 2025 |
Securities and Exchange Commission Exhibit 16.1 October 16, 2025 Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Dear Ladies and Gentlemen: We are the former independent registered public accounting firm for Solana Company (formerly known as Helius Medical Technologies, Inc.) (the “Company”). We have read the Company’s disclosure set forth in Item 4.01 “Changes in Registrant’s Certifying Accountant” of the |
|
| October 14, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| October 2, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| September 29, 2025 |
THIRD AMENDED AND RESTATED BYLAWS OF SOLANA COMPANY (A DELAWARE CORPORATION) Table of Contents Exhibit 3.2 THIRD AMENDED AND RESTATED BYLAWS OF SOLANA COMPANY (A DELAWARE CORPORATION) Table of Contents Page ARTICLE I Offices 1 Section 1. Registered Office 1 Section 2. Other Offices 1 ARTICLE II Corporate Seal 1 Section 3. Corporate Seal 1 ARTICLE III Stockholders’ Meetings 1 Section 4. Place of Meetings 1 Section 5. Annual Meeting 1 Section 6. Special Meetings 8 Section 7. Notice of Meeting |
|
| September 29, 2025 |
Exhibit 99.1 Preeminent SOL Treasury Company Helius (NASDAQ:HSDT) Announces Corporate Name Change to Solana Company and Letter of Intent with Solana Foundation HSDT Solana Company's Mission is to maximize SOL per share on one of the most commercially viable blockchains for consumer applications while delivering consistent on-chain yield for investors HSDT enters into agreement with the Solana Foun |
|
| September 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 2025 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38445 36-4787690 (State or other jurisdiction (Commission File |
|
| September 29, 2025 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF HELIUS MEDICAL TECHNOLOGIES, INC. (Pursuant to Section 242 of the General Corporation Law of the State of Delaware) Helius Medical Technologies, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify that: |
|
| September 25, 2025 |
Exhibit 10.2 642 Newtown Yardley Road, Suite 100 Newtown, PA 18940 215.944.6100 https://heliusmedical.com/ September 24, 2025 Personal and Confidential Jeffrey S. Mathiesen 12784 Kinross Lane Naples, Florida 34120 Re: Project Sumtera Dear Mr. Mathiesen: This Letter Agreement (this “Letter Agreement”) is entered into by and between Helius Medical Technologies, Inc., a Delaware corporation (the “Com |
|
| September 25, 2025 |
Helius Announces FDA 510(k) Submission for PoNS® Device Label Expansion in Stroke Exhibit 99.1 Helius Announces FDA 510(k) Submission for PoNS® Device Label Expansion in Stroke Seeking an indication for gait and balance deficit in patients with chronic symptoms of stroke under its Breakthrough Device Designation NEWTOWN, Pa., Sept 25, 2025 (GLOBE NEWSWIRE) - Helius Medical Technologies, Inc. (NASDAQ: HSDT), today announced the filing of its U.S. Food and Drug Administration (FD |
|
| September 25, 2025 |
Exhibit 10.1 642 Newtown Yardley Road, Suite 100 Newtown, PA 18940 215.944.6100 https://heliusmedical.com/ September 24, 2025 Personal and Confidential Dane C. Andreeff 140 East St. Lucia Lane Santa Rosa Beach, Florida 32459 Re:Project Sumtera Dear Mr. Andreeff: This Letter Agreement (this “Letter Agreement”) is entered into by and between Helius Medical Technologies, Inc., a Delaware corporation |
|
| September 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 24, 2025 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) - Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporati |
|
| September 22, 2025 |
Helius (NASDAQ:HSDT) Begins Purchases of SOL, the Native Asset of Solana Blockchain Exhibit 99.1 Helius (NASDAQ:HSDT) Begins Purchases of SOL, the Native Asset of Solana Blockchain Newtown, Pa. – September 22, 2025 – Helius Medical Technologies, Inc. (the "Company" or "HSDT"), today announced its first acquisition of Solana (“SOL”) tokens as part of its digital asset treasury strategy under which the principal holding will be SOL, the native digital asset of the Solana Blockchain |
|
| September 22, 2025 |
Helius Medical Technologies, Inc. Dated as of ___________, 20__ [ ] TABLE OF CONTENTS Exhibit 4.2 Helius Medical Technologies, Inc. INDENTURE Dated as of , 20 [ ] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions. 1 Section 1.2. Other Definitions. 4 Section 1.3. Incorporation by Reference of Trust Indenture Act. 4 Section 1.4. Rules of Construction. 5 ARTICLE II. THE SECURITIES 5 Section 2.1. Issuable in Series. 5 Sectio |
|
| September 22, 2025 |
As filed with the Securities and Exchange Commission on September 19, 2025 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on September 19, 2025 Registration No. |
|
| September 22, 2025 |
Calculation of Filing Fee Tables S-3 HELIUS MEDICAL TECHNOLOGIES, INC. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry F |
|
| September 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 22, 2025 Helius Medical Technologies, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38445 36-4787690 (State or Other Jurisdiction (Commission (IRS Emp |
|
| September 18, 2025 |
Exhibit 10.1 MASTER LENDER AGREEMENT This Master Lender Agreement (“Agreement”) is made on this (“Effective Date”) by and between FalconX Charlie, Inc, (“Lender”), a corporation organized and existing under the laws of Delaware with its principal place of business at 1850 Gateway Drive, 6th floor San Mateo CA, 94404 US and Marvel Operations Corp, (“Borrower”) a corporation residing and existing un |
|
| September 18, 2025 |
Exhibit 10.3 EXECUTIVE CHAIRMAN LETTER THIS AGREEMENT is made and entered into effective as September 18, 2025 (the “Effective Date”), by and between Helius Medical Technologies, Inc., a Delaware corporation (the “Company”) and Joseph Chee, an individual (“Director”) with his principal residence at A-38A-02, Tropicana Grande Condos, Tropicana Golf & Country Resort, 47410 Petaling Jaya, Selangor, M |
|
| September 18, 2025 |
CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION HELIUS MEDICAL TECHNOLOGIES, INC. Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF HELIUS MEDICAL TECHNOLOGIES, INC. Helius Medical Technologies, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify that: FIRST: The name of the Corporation is Helius Medical Technologies, Inc. and the da |
|
| September 18, 2025 |
AMENDED AND RESTATED INDEMNIFICATION AND ADVANCEMENT AGREEMENT Exhibit 10.2 AMENDED AND RESTATED INDEMNIFICATION AND ADVANCEMENT AGREEMENT This Amended and Restated Indemnification and Advancement Agreement (this “Agreement”) is made as of September [●], 2025 by and between Helius Medical Technologies, Inc., a Delaware corporation (the “Company”), and [●], a member of the Board of Directors or an officer of the Company (“Indemnitee”). This Agreement supersede |
|
| September 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2025 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38445 36-4787690 (State or other jurisdiction (IRS Employer of |
|
| September 18, 2025 |
Exhibit 99.1 Helius (NASDAQ:HSDT), in Partnership with Pantera Capital and Summer Capital Closes Over $500 Million Private Placement to Launch SOL Treasury Company Preeminent SOL-backed treasury vehicle - with potential to raise over $1.25 billion aggregate gross proceeds - unlocks capital markets to accelerate Solana’s growth The financing drew participation from leading investors across traditio |
|
| September 15, 2025 |
Exhibit 4.2 Form of Pre-Funded Warrant THIS WARRANT AND THE SHARES OF CLASS A COMMON STOCK ISSUABLE UPON THE EXERCISE OF THIS WARRANT (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, ASS |
|
| September 15, 2025 |
EXHIBIT 4.4 FORM OF WARRANT AGREEMENT THIS WARRANT AGREEMENT (this “Agreement”), dated as of September [●], 2025, is by and between Helius Medical Technologies, Inc., a Delaware corporation (the “Company”), and Equiniti Trust Company, LLC, as warrant agent (in such capacity, the “Warrant Agent,” and also referred to herein as the “Transfer Agent”). WHEREAS, the Company desires to sell to each Subs |
|
| September 15, 2025 |
EXHIBIT 10.5 TRADING ADVISORY AGREEMENT This TRADING ADVISORY AGREEMENT (this “Agreement”), effective as of this 15th day of September 2025, is between Pantera Capital Management LP, a Delaware limited partnership (the “Advisor”), and Helius Medical Technologies, Inc. (the “Client”). RECITALS The Client wishes to retain the Advisor to provide trading management services upon the terms and conditio |
|
| September 15, 2025 |
FORM OF STRATEGIC ADVISORY WARRANT Exhibit 4.5 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| September 15, 2025 |
Strictly Private & Confidential Project Sumtera Investor Presentation September 2025 Exhibit 99.2 Strictly Private & Confidential Project Sumtera Investor Presentation September 2025 2 Strictly Private & Confidential Disclaimer This presentation has been prepared by Helius Medical Technologies, Inc. (“Helius” or the “Company”) solely for information p urp oses. The information contained in this presentation has been prepared solely to assist interested parties in making their ow n |
|
| September 15, 2025 |
Exhibit 10.4 STRATEGIC ADVISORY AGREEMENT This Strategic Advisory Agreement (this “Agreement”) is entered into as of September 15, 2025 (the “Effective Date”) by and between Helius Medical Technologies, Inc. (the “Customer”), Pantera Capital Management LP, a Delaware limited partnership (“Pantera”) and Summer Wisdom Holdings Limited, a BVI business company incorporated in British Virgin Island (“S |
|
| September 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 15, 2025 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38445 36-4787690 (State or other jurisdiction (Commission (IRS |
|
| September 15, 2025 |
Risks Related to Our Solana and Digital Asset Treasury Strategy Exhibit 99.3 Risks Related to Our Solana and Digital Asset Treasury Strategy Our Solana strategy exposes us to various risks, including risks associated with Solana. Our Solana strategy exposes us to various risks, including the following: Solana is a highly volatile asset. Solana is a highly volatile asset that has traded below $140 per Solana and above $240 per Solana on the Coinbase exchange (a |
|
| September 15, 2025 |
EXHIBIT 10.1 SUBSCRIPTION AGREEMENT This SUBSCRIPTION AGREEMENT (this “Subscription Agreement”) is entered into on September 15, 2025, by and among Helius Medical Technologies, Inc., a Delaware corporation (the “Issuer”), and the undersigned investors (collectively, the “Subscribers” and each a “Subscriber”). This Subscription Agreement may be executed by an investment manager on behalf of one or |
|
| September 15, 2025 |
EXHIBIT 4.3 FORM OF WARRANT AGREEMENT THIS WARRANT AGREEMENT (this “Agreement”), dated as of September [●], 2025, is by and between Helius Medical Technologies, Inc., a Delaware corporation (the “Company”), and Equiniti Trust Company, LLC, as warrant agent (in such capacity, the “Warrant Agent,” and also referred to herein as the “Transfer Agent”). WHEREAS, the Company desires to sell to each Subs |
|
| September 15, 2025 |
Helius Medical Technologies, Inc. Up to $92,800,000 of Class A Common Stock TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-270433 PROSPECTUS SUPPLEMENT (To Prospectus dated May 26, 2023) Helius Medical Technologies, Inc. Up to $92,800,000 of Class A Common Stock We entered into a Sales Agreement, dated September 15, 2025 (the “Sales Agreement”), with Clear Street LLC (“Clear Street”) and Maxim Group LLC (“Maxim,” and together with Clear Street, |
|
| September 15, 2025 |
EXHIBIT 10.2 SUBSCRIPTION AGREEMENT This SUBSCRIPTION AGREEMENT (this “Subscription Agreement”) is entered into on September 15, 2025, by and among Helius Medical Technologies, Inc., a Delaware corporation (the “Issuer”), and the undersigned investors (collectively, the “Subscribers” and each a “Subscriber”). This Subscription Agreement may be executed by an investment manager on behalf of one or |
|
| September 15, 2025 |
Exhibit 4.1 Form of Pre-Funded Warrant THIS WARRANT AND THE SHARES OF CLASS A COMMON STOCK ISSUABLE UPON THE EXERCISE OF THIS WARRANT (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, ASS |
|
| September 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2025 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38445 36-4787690 (State or other jurisdiction (IRS Employer of |
|
| September 15, 2025 |
Exhibit 10.3 LOCK-UP AGREEMENT HELIUS MEDICAL TECHNOLOGIES, INC. 642 Newtown Yardley Road, Suite 100 Newtown, Pennsylvania 18940 This agreement (this “Lock-up Agreement”) is being delivered to you in connection with the proposed private placement offering of (i) shares of Class A common stock, par value 0.001 per share (the “Common Stock”) of Helius Medical Technologies, Inc., a Delaware corporati |
|
| September 15, 2025 |
Exhibit 99.1 Helius (NASDAQ:HSDT), in Partnership with Pantera Capital and Summer Capital Announces Over $500 Million in Funding to Launch SOL Treasury Company Preeminent SOL-backed treasury vehicle - with potential to deliver over $1.25 billion - unlocks capital markets to accelerate Solana’s growth ● The offering was led by institutional and crypto-native investors such as Pantera Capital, Summe |
|
| September 15, 2025 |
HELIUS MEDICAL TECHNOLOGIES, INC. Class A Common Stock ($0.001 par value per share) Sales Agreement Exhibit 1.1 HELIUS MEDICAL TECHNOLOGIES, INC. Class A Common Stock ($0.001 par value per share) Sales Agreement September 15, 2025 Clear Street LLC 4 World Trade Center 150 Greenwich Street, 45th Floor New York, NY 10007 Maxim Group LLC 300 Park Avenue, 16th Floor New York, NY 10022 Ladies and Gentlemen: Helius Medical Technologies, Inc., a Delaware corporation (the “Company”), confirms its agreem |
|
| August 14, 2025 |
Placement Agency Agreement dated June 4, 2025 by and between the Company and Maxim Group LLC Exhibit 10.4 PLACEMENT AGENCY AGREEMENT June 4, 2025 Maxim Group LLC 300 Park Avenue, 16th Floor New York, NY 10022 Ladies and Gentlemen: Subject to the terms and conditions herein (this “Agreement”), Helius Medical Technologies, Inc., a Delaware corporation (including any successor thereto, the “Company”), hereby agrees to sell up to an aggregate of $9,053,322 of units, each unit consisting of (1 |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-38445 HELIUS |
|
| July 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21, 2025 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) - Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporation) ( |
|
| July 10, 2025 |
Second Amendment to the Helius Medical Technologies, Inc. 2022 Equity Incentive Plan Exhibit 4.11 AMENDMENT 2 TO HELIUS MEDICAL TECHNOLOGIES, INC. 2022 Equity Incentive Plan RECITALS A. Helius Medical Technologies, Inc., a Delaware corporation (the “Company”) sponsors the Helius Medical Technologies, Inc. 2022 Equity Incentive Plan, as amended (the “Plan”). B. The Plan is amended by this Amendment 2 (this “Second Amendment”) in the following respects, effecti |
|
| July 10, 2025 |
Exhibit 107 Calculation of Filing Fee Table FORM S-8 (Form Type) Helius Medical Technologies, Inc. |
|
| July 10, 2025 |
As filed with the Securities and Exchange Commission on July 10, 2025 Registration No. |
|
| July 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2025 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) - Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporation) (C |
|
| July 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2025 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38445 36-4787690 (State or other jurisdiction (IRS Employer of incor |
|
| July 7, 2025 |
Helius Medical Technologies, Inc. Up to $25,000,000 Class A Common Stock TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-270433 PROSPECTUS SUPPLEMENT (To Prospectus Supplements dated June 23, 2023 and March 26, 2025 and Prospectus dated May 25, 2023) Helius Medical Technologies, Inc. Up to $25,000,000 Class A Common Stock This prospectus supplement amends and supplements the prospectus supplements, dated June 23, 2023 and March 26, 2025 (the |
|
| June 27, 2025 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF HELIUS MEDICAL TECHNOLOGIES, INC. Helius Medical Technologies, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify that: FIRST: The name of the Corporation is Helius Medical Technologies, Inc. and the da |
|
| June 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2025 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) - Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporation) ( |
|
| June 23, 2025 |
Helius Medical Technologies, Inc. Unaudited Condensed Interim Consolidated Balance Sheet Exhibit 99.1 Helius Medical Technologies, Inc. Unaudited Condensed Interim Consolidated Balance Sheet The unaudited balance sheet has been filed in order to show compliance with the Nasdaq requirement that the Company maintain a minimum stockholders' equity of $2.5 million for continued listing. The unaudited balance sheet presents the Company’s balance sheet as June 17, 2025 and gives effect to t |
|
| June 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2025 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) - Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporation) ( |
|
| June 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2025 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) - Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporation) ( |
|
| June 6, 2025 |
TABLE OF CONTENTS Filed pursuant to Rule 424(b)(4) Registration No. 333-287572 PROSPECTUS HELIUS MEDICAL TECHNOLOGIES, INC. 2,627,050 Shares of Common Stock or Pre-Funded Warrants to Purchase up to 141,550 Shares of Common Stock, Common Warrants to Purchase up to 2,768,600 Shares of Common Stock and Placement Agent Warrants to Purchase up to 138,430 Shares of Common Stock Up to 45,122,565 Shares |
|
| June 4, 2025 |
Exhibit 99.1 Helius Medical Technologies, Inc. Compliant with Nasdaq Bid Price Rule Listing Criteria -Company previously granted extension until June 30, 2025 to regain compliance with Nasdaq’s Equity Rule requirement- NEWTOWN, Pa., June 4, 2025 (GLOBE NEWSWIRE) - Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeu |
|
| June 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2025 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38445 36-4787690 (State or other jurisdiction (IRS Employer of incor |
|
| June 3, 2025 |
June 3, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Helius Medical Technologies, Inc. Registration Statement on Form S-1 File No. 333-287572 Ladies and Gentlemen: Maxim Group LLC (“Maxim”), as placement agent, hereby respectfully requests the withdrawal of its acceleration request letter filed as correspondenc |
|
| June 2, 2025 |
June 2, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F. Street, NE Washington, D.C. 20549 Attention: Nick O’Leary Re: Helius Medical Technologies, Inc. Registration Statement on Form S-1 File No. 333-287572 Acceleration Request Requested Date: June 4, 2025 Requested Time: 5:00 P.M. Eastern Time Ladies and Gentlemen: Helius Medical Technologies, Inc. (t |
|
| May 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38445 (Commission file number) 642 Newtown Yardley Road, Suite 100 Newtown, PA (Address of principal executive offices) 18940 (Zip Code) Dane |
|
| May 30, 2025 |
Exhibit 1.01 Helius Medical Technologies, Inc. Conflict Minerals Report For Calendar Year 2024 Helius Medical Technologies, Inc. (“Helius,” the “Company,” “we” and “our”) submits this Conflict Minerals Report for the period January 1 to December 31, 2024, pursuant to Rule 13p-1 under the Securities Exchange Act of 1934, as amended (the “Rule”). The Rule was adopted by the Securities and Exchange C |
|
| May 28, 2025 |
May 28, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F. Street, NE Washington, D.C. 20549 Attention: Jessica Ansart Re: Helius Medical Technologies, Inc. Registration Statement on Form S-1 File No. 333-287572 Acceleration Request Requested Date: May 29, 2025 Requested Time: 5:00 P.M. Eastern Time Ladies and Gentlemen: Pursuant to Rule 461 under the Sec |
|
| May 28, 2025 |
May 28, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Helius Medical Technologies, Inc. Registration Statement on Form S-1 File No. 333-287572 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations of the U.S. Securities and Exchange Commission under the Securities Act of 1933, as amend |
|
| May 23, 2025 |
Exhibit 4.4 PRE-FUNDED COMMON STOCK PURCHASE WARRANT HELIUS MEDICAL TECHNOLOGIES, INC. Warrant Shares: Initial Exercise Date: , 2025 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after th |
|
| May 23, 2025 |
As filed with the Securities and Exchange Commission on May 23, 2025. TABLE OF CONTENTS As filed with the Securities and Exchange Commission on May 23, 2025. |
|
| May 23, 2025 |
Form of Securities Purchase Agreement Exhibit 10.25 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May , 2025, between Helius Medical Technologies, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and con |
|
| May 23, 2025 |
Form of Common Warrant to Purchase Shares of Common Stock Exhibit 4.2 COMMON STOCK PURCHASE WARRANT HELIUS MEDICAL TECHNOLOGIES, INC. Warrant Shares: Initial Exercise Date: , 2025 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “In |
|
| May 23, 2025 |
Form of Placement Agency Agreement Exhibit 10.24 PLACEMENT AGENCY AGREEMENT May [·], 2025 Maxim Group LLC 300 Park Avenue, 16th Floor New York, NY 10022 Ladies and Gentlemen: Subject to the terms and conditions herein (this “Agreement”), Helius Medical Technologies, Inc., a Delaware corporation (including any successor thereto, the “Company”), hereby agrees to sell up to an aggregate of $ of units, each unit consisting of (1) eithe |
|
| May 23, 2025 |
Exhibit 107 Calculation of Filing Fee Table FORM S-1 (Form Type) Helius Medical Technologies, Inc. |
|
| May 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2025 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) - Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporation) (C |
|
| May 23, 2025 |
Form of Placement Agent Warrant to Purchase Shares of Common Stock Exhibit 4.3 PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT HELIUS MEDICAL TECHNOLOGIES, INC. Warrant Shares: Initial Exercise Date: , 2025 THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on o |
|
| May 2, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| May 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-38445 HELIUS |
|
| April 30, 2025 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF HELIUS MEDICAL TECHNOLOGIES, INC. Helius Medical Technologies, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify that: FIRST: The name of the Corporation is Helius Medical Technologies, Inc. and the da |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2025 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) - Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporation) |
|
| April 30, 2025 |
Helius Medical Technologies Announces Reverse Stock Split Exhibit 99.1 Helius Medical Technologies Announces Reverse Stock Split NEWTOWN, Pa., April 30, 2025 (GLOBE NEWSWIRE) - Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, announced today a 1-for-15 reverse split of its Class A common stock, par value $0.001 |
|
| April 25, 2025 |
Exhibit 4.1 [FORM OF SENIOR NOTE] THIS SECURITY HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT |
|
| April 25, 2025 |
Exhibit 10.3 FORM OF LOCK-UP AGREEMENT , 2025 Re: Securities Purchase Agreement, dated as of , 2025 (the “Purchase Agreement”), between Helius Medical Technologies, Inc. (the “Company”) and the purchasers signatory thereto (each, a “Purchaser” and, collectively, the “Purchasers”) Ladies and Gentlemen: Defined terms not otherwise defined in this letter agreement (the “Letter Agreement”) shall have |
|
| April 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2025 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) - Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporation) |
|
| April 25, 2025 |
Form of Placement Agency Agreement Exhibit 10.2 April 24, 2025 Dane C. Andreeff President and Chief Executive Officer Helius Medical Technologies, Inc. 642 Newtown Yardley Road, Suite 100 Newtown, Pennsylvania 18940 Dear Mr. Andreeff: This letter (the “Agreement”) constitutes the agreement between Maxim Group LLC (“Maxim” or the “Placement Agent”) and Helius Medical Technologies, Inc., a Delaware corporation, (the “Company”), that |
|
| April 25, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of April 24, 2025, between Helius Medical Technologies, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (including their respective successors and assigns, each a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to t |
|
| April 22, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| April 22, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 21, 2025 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) - Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporation) |
|
| April 21, 2025 |
April 21, 2025 Dane C. Andreeff President and Chief Executive Officer Helius Medical Technologies, Inc. 642 Newtown Yardley Road, Suite 100 Newtown, Pennsylvania 18940 Re: Helius Medical Technologies, Inc. Draft Registration Statement on Form S-1 Submitted April 15, 2025 CIK No. 0001610853 Dear Dane C. Andreeff: This is to advise you that we do not intend to review your registration statement. We |
|
| April 15, 2025 |
TABLE OF CONTENTS As confidentially submitted with the Securities and Exchange Commission on April 15, 2025. |
|
| April 15, 2025 |
CONFIDENTIAL SUBMISSION VIA EDGAR CONFIDENTIAL SUBMISSION VIA EDGAR April 15, 2025 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Re: Helius Medical Technologies, Inc. Draft Registration Statement on Form S-1 Confidentially Submitted on April 15, 2025 CIK No. 0001610853 Ladies and Gentlemen: On behalf of Helius Medical Technologies, Inc. (the “Company”), we have c |
|
| April 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the Fiscal Year Ended December 31, 2024 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File No. 001-38445 HELIUS MEDICAL TECHNOLOGIES |
|
| April 4, 2025 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2025 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) - Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporation) |
|
| March 26, 2025 |
Helius Medical Technologies, Inc. Up to $1,444,764 Class A Common Stock TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-270433 PROSPECTUS SUPPLEMENT (To Prospectus Supplement dated June 23, 2023 and Prospectus Dated May 25, 2023) Helius Medical Technologies, Inc. Up to $1,444,764 Class A Common Stock This prospectus supplement amends and supplements the information in the sales agreement prospectus, dated May 25, 2023 (the “Prospectus”), file |
|
| March 26, 2025 |
Helius Medical Technologies, Inc. 642 Newtown Yardley Road, Suite 100 Newtown, PA 1894 Helius Medical Technologies, Inc. 642 Newtown Yardley Road, Suite 100 Newtown, PA 1894 March 26, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F. Street, NE Washington, D.C. 20549 Attention: Margaret Sawicki Re: Helius Medical Technologies, Inc. Registration Statement on Form S-3 Filed January 31, 2025 File No. 333-284633 Acceleration Request Lad |
|
| March 25, 2025 |
Exhibit 10.9.1 660 Tudor Square, L.P. Lease Addendum #1 LANDLORD:660 Tudor Square, L.P. TENANT:Helius Medical Technologies, Inc. PREMISES:642 Newtown Yardley Rd, Suite 215 CURRENT LEASE TERM:January 1, 2022 - March 31, 2025 1. This lease shall be extended for one (1) additional year, ending March 31, 2026. 2. The Minimum Base Rent Schedule shall be as follows: 04/01/2025 - 03/31/2026$3,750.00/mont |
|
| March 25, 2025 |
As filed with the Securities and Exchange Commission on March 25, 2025 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on March 25, 2025 Registration No. |
|
| March 25, 2025 |
Exhibit 19.1 Helius Medical Technologies, Inc. Insider Trading Compliance Policy Effective November 21, 2023 This Insider Trading Compliance Policy (this “Policy”) consists of four sections: Section I provides an overview; Section II sets forth the policies of HELIUS MEDICAL TECHNOLOGIES, INC., a Delaware corporation (the “Company”) prohibiting insider trading; Section III explains insider trading |
|
| March 25, 2025 |
Exhibit 10.9 COMMERCIAL LEASE AGREEMENT ¾ SUMMARY OF BASIC TERMS THIS LEASE AGREEMENT, made this 29th day of November, 2021, by and between Helius Medical Technologies, Inc. (hereinafter referred to as Tenant) and 660 Tudor Square, L.P. (hereinafter referred to as Landlord). WITNESSETH: The Landlord, for and in consideration of the prompt payment of the rent as specified in this Agreement as well |
|
| March 25, 2025 |
Subsidiaries of Helius Medical Technologies, Inc. Exhibit 21.1 SUBSIDIARIES OF HELIUS MEDICAL TECHNOLOGIES, INC ENTITY NAME JURISDICTION Helius Medical, Inc. Delaware Revelation Neuro, Inc. Texas Helius Medical Technologies (Canada), Inc. Canada |
|
| March 25, 2025 |
Exhibit 107 Calculation of Filing Fee Table FORM S-8 (Form Type) Helius Medical Technologies, Inc. |
|
| March 25, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rul |
|
| March 25, 2025 |
As filed with the Securities and Exchange Commission on March 25, 2025 Registration No. |
|
| March 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the Fiscal Year Ended December 31, 2024 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File No. 001-38445 HELIUS ME |
|
| March 14, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rul |
|
| February 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2025 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) - Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporation |
|
| February 5, 2025 |
February 5, 2025 Dane C. Andreeff President, Chief Executive Officer and Director HELIUS MEDICAL TECHNOLOGIES, INC. 642 Newtown Yardley Road, Suite 100 Newtown, Pennsylvania 18940 Re: HELIUS MEDICAL TECHNOLOGIES, INC. Registration Statement on Form S-3 Filed January 31, 2025 File No. 333-284633 Dear Dane C. Andreeff: This is to advise you that we have not reviewed and will not review your registra |
|
| January 31, 2025 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Registration Statement Form S-3 (Form Type) Helius Medical Technologies, Inc. |
|
| January 31, 2025 |
As filed with the Securities and Exchange Commission on January 31, 2025 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on January 31, 2025 Registration No. |
|
| January 24, 2025 |
Exhibit 99.1 Helius Medical Technologies, Inc. Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $3.7 Million Gross Proceeds Priced At-the-Market NEWTOWN, Pa., Jan. 21, 2025 (GLOBE NEWSWIRE) - Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for ba |
|
| January 24, 2025 |
Exhibit 10.1 January 21, 2025 To Holder of Common Stock Purchase Warrants of Helius Medical Technologies, Inc. Re:Reload Offer of Common Stock Purchase Warrants To Whom It May Concern: Helius Medical Technologies, Inc. (the “Company”) is pleased to offer to you the opportunity to receive new Common Stock purchase warrants of the Company in consideration for the exercise of (i) the Series A Common |
|
| January 24, 2025 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| January 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 21, 2025 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) - Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporation |
|
| January 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporation) |
|
| December 23, 2024 |
Exhibit 99.1 Helius Announces First Portable Neuromodulation Stimulator (PoNS®) System Sale to the Veterans Affairs (VA) Healthcare System Initial order placed with Company’s distributor at contracted price and represents operational implementation through VA Federal Supply Schedule (FSS) Contract NEWTOWN, Pa., Dec. 23, 2024 (GLOBE NEWSWIRE) - Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Heli |
|
| December 23, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2024 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) - Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporatio |
|
| November 18, 2024 |
Exhibit 99.1 Helius Medical Technologies, Inc. Announces Exploration of Strategic Alternatives NEWTOWN, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) - Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced it has initiated a process, in consultation wit |
|
| November 18, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2024 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) - Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporatio |
|
| November 18, 2024 |
Exhibit 99.2 Helius Medical Technologies, Inc. Provides Updates on Efforts to Achieve Fair Market Access for its Portable Neuromodulation Stimulator (PoNS®) Device Management to host business update call today at 9:00am ET NEWTOWN, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) - Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel the |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-38445 HE |
|
| November 8, 2024 |
SC 13G/A 1 hsdt13ga.htm HSDT 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Helius Medical Technologies, Inc. (Name of Issuer) Class A Common Stock, par value $0.001 per share (Title of Class of Securities) 42328V801 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) |
|
| August 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-38445 HELIUS |
|
| August 12, 2024 |
Exhibit 99.1 Helius Medical Technologies, Inc. Reports Second Quarter 2024 Financial Results - Company to host call at 4:30pm today - NEWTOWN, Pa., Aug. 12, 2024 (GLOBE NEWSWIRE) - Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced results |
|
| August 12, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 12, 2024 Date of Report (Date of earliest event reported) HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of Registrant as Specified in Its Charter) - DELAWARE 001-38445 36-4787690 (State or Other Jurisdiction of Incorporation) |
|
| August 9, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2024 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) - Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporation) |
|
| July 24, 2024 |
Exhibit 4.8 Helius Medical Technologies, Inc. 2021 Inducement Plan Adopted by the Board of Directors: July 1, 2021 Amended by the Board of Directors: July 2, 2024 1. General. (a) Eligible Award Recipients. The only persons eligible to receive grants of Awards under this Plan are individuals who satisfy the standards for inducement grants under Nasdaq Marketplace Rule 5635(c |
|
| July 24, 2024 |
As filed with the Securities and Exchange Commission on July 24, 2024 Registration No. |
|
| July 24, 2024 |
Exhibit 107 Calculation of Filing Fee Table FORM S-8 (Form Type) Helius Medical Technologies, Inc. |
|
| June 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2024 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) - Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporation) ( |
|
| June 28, 2024 |
Exhibit 10.1 AMENDMENT 1 TO HELIUS MEDICAL TECHNOLOGIES, INC. 2022 Equity Incentive Plan RECITALS A.Helius Medical Technologies, Inc., a Delaware corporation (the “Company”) sponsors the Helius Medical Technologies, Inc. 2022 Equity Incentive Plan (the “Plan”). B.The Plan is amended by this Amendment 1 (this “First Amendment”) in the following respects, effective from and after the date this First |
|
| June 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi |
|
| June 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2024 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) - Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporation) (C |
|
| May 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2024 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) - Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporation) (C |
|
| May 31, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rul |
|
| May 31, 2024 |
81,7('67$7(6 6(&85,7,(6$1'(;&+$1*(&200,66,21 :DVKLQJWRQ'& )250. |
|
| May 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38445 (Commission file number) 642 Newtown Yardley Road, Suite 100 Newtown, PA (Address of principal executive offices) 18940 (Zip Code) Dane |
|
| May 30, 2024 |
Exhibit 1.01 Helius Medical Technologies, Inc. Conflict Minerals Report For Calendar Year 2023 Helius Medical Technologies, Inc. (“Helius,” the “Company,” “we” and “our”) submits this Conflict Minerals Report for the period January 1 to December 31, 2023 pursuant to Rule 13p-1 under the Securities Exchange Act of 1934, as amended (the “Rule”). The Rule was adopted by the Securities and Exchange Co |
|
| May 14, 2024 |
SC 13G 1 ea0206042-13gintrahelius.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Helius Medical Technologies, Inc. (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 42328V801 (CUSIP Number) May 9, 2024 (Date of Event Which Requires Filing of this |
|
| May 14, 2024 |
EX-99.1 2 ea020604201ex99-1helius.htm JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessity of filing additional joint filing ag |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 13, 2024 Date of Report (Date of earliest event reported) HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of Registrant as Specified in Its Charter) - DELAWARE 001-38445 36-4787690 (State or Other Jurisdiction of Incorporation) (Co |
|
| May 13, 2024 |
Exhibit 99.1 Helius Medical Technologies, Inc. Reports First Quarter 2024 Financial Results - Company to host call at 4:30pm today - NEWTOWN, Pa., May 13, 2024 (GLOBE NEWSWIRE) - Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced results fo |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-38445 HELIUS |
|
| May 9, 2024 |
Exhibit 10.1 PLACEMENT AGENCY AGREEMENT May 6, 2024 VIA ELECTRONIC DELIVERY Mr. Dane C. Andreeff President and Chief Executive Officer Helius Medical Technologies, Inc. 642 Newtown Yardley Road, Suite 100 Newtown, Pennsylvania 18940 Dear Mr. Andreeff: This letter (the “Agreement”) constitutes the agreement between Craig-Hallum Capital Group LLC (“Craig-Hallum” or the “Placement Agent”) and Helius |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2024 Helius Medical Technologies, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38445 36-4787690 (State or Other Jurisdiction of Incorporation) (Comm |
|
| May 9, 2024 |
Exhibit 4.1 FORM OF SERIES A COMMON STOCK PURCHASE WARRANT HELIUS MEDICAL TECHNOLOGIES, INC. Warrant Shares: Initial Exercise Date: May 9, 2024 Issue Date: May 9, 2024 THIS SERIES A COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set |
|
| May 9, 2024 |
Exhibit 4.3 PLACEMENT AGENT WARRANT HELIUS MEDICAL TECHNOLOGIES, INC. Warrant Shares: Initial Issuance Date: May 9, 2024 THIS PLACEMENT AGENT WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, , or its assigns (the “Holder”), is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after (Ma |
|
| May 9, 2024 |
Helius Medical Technologies, Inc. Announces Pricing of $6.4 Million Public Offering Exhibit 99.1 Helius Medical Technologies, Inc. Announces Pricing of $6.4 Million Public Offering NEWTOWN, Pa., May 6, 2024 – Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced the pricing of a public offering of 804,999 shares of its Class |
|
| May 9, 2024 |
Exhibit 4.2 FORM OF SERIES B COMMON STOCK PURCHASE WARRANT HELIUS MEDICAL TECHNOLOGIES, INC. Warrant Shares: Initial Exercise Date: May 9, 2024 Issue Date: May 9, 2024 THIS SERIES B COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set |
|
| May 9, 2024 |
Exhibit 4.4 PRE-FUNDED COMMON STOCK PURCHASE WARRANT HELIUS MEDICAL TECHNOLOGIES, INC. Warrant Shares: Initial Exercise Date: May 9, 2024 Issue Date: May 9, 2024 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set fort |
|
| May 8, 2024 |
TABLE OF CONTENTS Filed pursuant to Rule 424(b)(4) Registration No. 333-278698 PROSPECTUS HELIUS MEDICAL TECHNOLOGIES, INC. 704,999 Shares of Common Stock Series A Warrants to Purchase up to 2,852,221 Shares of Common Stock Series B Warrants to Purchase up to 2,852,221 Shares of Common Stock Pre-Funded Warrants to Purchase up to 2,147,222 Shares of Common Stock This is a best efforts public offe |
|
| May 6, 2024 |
Exhibit 99.1 Helius Medical Technologies, Inc. Announces Preliminary CMS Payment Determination of Reimbursement for Portable Neuromodulation Stimulator (PoNS®) - The Centers for Medicare & Medicaid Services (CMS) released its preliminary Medicare payment determinations for the PoNS Controller and Mouthpiece - - Public Meeting Scheduled for May 29, 2024 - NEWTOWN, Pa., May 6, 2024– Helius Medical T |
|
| May 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2024 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) - Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporation) (Co |
|
| May 3, 2024 |
May 3, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F. Street, NE Washington, D.C. 20549 Attention: Benjamin Richie Re: Helius Medical Technologies, Inc. Registration Statement on Form S-1 File No. 333-278698 Acceleration Request Requested Date: May 6, 2024 Requested Time: 5:00 P.M. Eastern Time Ladies and Gentlemen: Pursuant |
|
| May 2, 2024 |
May 2, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F. Street, NE Washington, D.C. 20549 Re: Helius Medical Technologies, Inc. Registration Statement on Form S-1, as amended File No. 333-278698 Withdrawal of Acceleration Request Ladies and Gentlemen: Reference is made to our letter filed as correspondence with the U.S. Securities and Exchange Commissio |
|
| May 1, 2024 |
May 1, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F. Street, NE Washington, D.C. 20549 Attention: Benjamin Richie Re: Helius Medical Technologies, Inc. Registration Statement on Form S-1 File No. 333-278698 Acceleration Request Requested Date: May 2, 2024 Requested Time: 4:05 P.M. Eastern Time Ladies and Gentlemen: Pursuant to Rule 461 under the Secu |
|
| April 26, 2024 |
Exhibit 4.4 PRE-FUNDED COMMON STOCK PURCHASE WARRANT HELIUS MEDICAL TECHNOLOGIES, INC. Warrant Shares: Initial Exercise Date: Issue Date: THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or aft |
|
| April 26, 2024 |
Exhibit 107 Calculation of Filing Fee Table FORM S-1 (Form Type) Helius Medical Technologies, Inc. |
|
| April 26, 2024 |
Exhibit 4.2 FORM OF SERIES A COMMON STOCK PURCHASE WARRANT HELIUS MEDICAL TECHNOLOGIES, INC. Warrant Shares: Initial Exercise Date: , 2024 Issue Date: , 2024 THIS SERIES A COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter se |
|
| April 26, 2024 |
Exhibit 4.3 FORM OF SERIES B COMMON STOCK PURCHASE WARRANT HELIUS MEDICAL TECHNOLOGIES, INC. Warrant Shares: Initial Exercise Date: , 2024 Issue Date: , 2024 THIS SERIES B COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter se |
|
| April 26, 2024 |
Form of Placement Agency Agreement Exhibit 10.24 PLACEMENT AGENCY AGREEMENT May , 2024 VIA ELECTRONIC DELIVERY Mr. Dane C. Andreeff President and Chief Executive Officer Helius Medical Technologies, Inc. 642 Newtown Yardley Road, Suite 100 Newtown, Pennsylvania 18940 Dear Mr. Andreeff: This letter (the “Agreement”) constitutes the agreement between Craig-Hallum Capital Group LLC (“Craig-Hallum” or the “Placement Agent”) and Helius |
|
| April 26, 2024 |
As filed with the U.S. Securities and Exchange Commission on April 26, 2024 TABLE OF CONTENTS As filed with the U.S. Securities and Exchange Commission on April 26, 2024 Registration No. 333-278698 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdic |
|
| April 26, 2024 |
Form of Placement Agent Warrant Exhibit 4.5 PLACEMENT AGENT WARRANT HELIUS MEDICAL TECHNOLOGIES, INC. Warrant Shares: Initial Issuance Date: May , 2024 THIS PLACEMENT AGENT WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, Craig-Hallum Capital Group, LLC, or its assigns (the “Holder”), is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set fort |
|
| April 23, 2024 |
United States securities and exchange commission logo April 23, 2024 Dane C. Andreeff Chief Executive Officer Helius Medical Technologies, Inc. 642 Newtown Yardley Road, Suite 100 Newtown, Pennsylvania 18940 Re: Helius Medical Technologies, Inc. Registration Statement on Form S-1 Filed April 15, 2024 File No. 333-278698 Dear Dane C. Andreeff: This is to advise you that we have not reviewed and wil |
|
| April 15, 2024 |
As filed with the U.S. Securities and Exchange Commission on April 15, 2024 TABLE OF CONTENTS As filed with the U.S. Securities and Exchange Commission on April 15, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporati |
|
| April 15, 2024 |
Exhibit 107 Calculation of Filing Fee Table FORM S-1 (Form Type) Helius Medical Technologies, Inc. |
|
| April 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2024 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) - Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporation) ( |
|
| March 28, 2024 |
Exhibit 99.1 Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results - Company to host call at 4:30pm today – NEWTOWN, Pa., March 28, 2024 (GLOBE NEWSWIRE) - Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today ann |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the Fiscal Year Ended December 31, 2023 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File No. 001-38445 HELIUS ME |
|
| March 28, 2024 |
Subsidiaries of Helius Medical Technologies, Inc. Exhibit 21.1 SUBSIDIARIES OF HELIUS MEDICAL TECHNOLOGIES, INC ENTITY NAME JURISDICTION Helius Medical, Inc. Delaware Helius Medical Technologies (Canada), Inc. Canada Helius NeuroRehab, Inc. Delaware Helius Canada Acquisition Ltd. Canada Heuro Canada, Inc. Canada |
|
| March 28, 2024 |
Exhibit 97.1 Helius Medical Technologies, Inc. Policy for the Recovery of Erroneously Awarded Compensation Adopted and approved on November 21, 2023 and Effective as of November 21, 2023 1.Purpose. The Board of Directors (the “Board”) of Helius Medical Technologies, Inc., a Delaware corporation (the “Company”) believes that it is in the best interests of the Company and its stockholders to adopt t |
|
| March 28, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 28, 2024 Date of Report (Date of earliest event reported) HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of Registrant as Specified in Its Charter) - DELAWARE 001-38445 36-4787690 (State or Other Jurisdiction of Incorporation) ( |
|
| March 15, 2024 |
Exhibit 3.1 SECOND AMENDED AND RESTATED BYLAWS OF helius medical technologies, Inc. (A DELAWARE CORPORATION) March 12, 2024 Table of Contents Page ARTICLE I Offices 1 Section 1. Registered Office 1 Section 2. Other Offices 1 ARTICLE II Corporate Seal 1 Section 3. Corporate Seal 1 ARTICLE III Stockholders’ Meetings 1 Section 4. Place of Meetings 1 Section 5. Annual Meeting. 1 Section 6. Special Mee |
|
| March 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2024 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) - Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporation) |
|
| March 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2024 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) - Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporation) ( |
|
| March 4, 2024 |
Exhibit 99.1 Helius Medical Technologies, Inc. Secures HCPCS Codes for Portable Neuromodulation Stimulator (PoNS®) Mouthpiece and Controller - Significant step toward reimbursement for the only medical device approved in the U.S. for treatment of gait deficit due to multiple sclerosis (“MS”) - - Proceeds from recent stock issuances through the Company’s At-The-Market (“ATM”) program extends cash r |
|
| February 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Helius Medical Technologies, Inc. - (Name of Issuer) Common Stock - (Title of Class of Securities) 42328V801 - (CUSIP Number) December 31, 2023 - (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule purs |
|
| February 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2024 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) - Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporation |
|
| February 6, 2024 |
SC 13G/A 1 ea192883-13ga2intrahelius.htm AMENDMENT NO. 2 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Helius Medical Technologies, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 42328V801 (CUSIP Number) December 31, 2023 (Date of Event |
|
| February 5, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Helius Medical Technologies, Inc. (Name of Issuer) Class A Common Stock, par value $0.001 per share (Title of Class of Securities) 42328V801 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designa |
|
| December 4, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 04, 2023 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) - Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporatio |
|
| December 4, 2023 |
Exhibit 99.1 Empowering Neuroplasticity PoNS TherapyTM for Balance and Gait Deficits in Patients with Neurological Disorders December 2023 NASDAQ:HSDT Legal Disclaimers This presentation contains forward-looking statements, including statements regarding the Company’s future strategic and operational execution, the success of the Company’s PoNS device and related treatment, the next phase of the C |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-38445 HE |
|
| November 9, 2023 |
Exhibit 99.1 Helius Medical Technologies, Inc. Reports Third Quarter 2023 Financial Results - Cash runway extended into Q2 2024 - - Company to host call at 4:30pm today – NEWTOWN, Pa., Nov. 9, 2023 (GLOBE NEWSWIRE) - Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gai |
|
| November 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 9, 2023 Date of Report (Date of earliest event reported) HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of Registrant as Specified in Its Charter) - DELAWARE 001-38445 36-4787690 (State or Other Jurisdiction of Incorporation) |
|
| November 2, 2023 |
Exhibit 99.1 Helius Medical Technologies, Inc. to Release Third Quarter 2023 Financial Results on November 9, 2023; Announces Extended Cash Runway into Q2 2024 - Expects to report Q3 revenues in range of $140 - $150 thousand, reflecting the expected decrease in U.S. sales with the conclusion of the Patient Therapy Access Program (PTAP) on June 30, 2023 - - Expects to report approximately $7.0 mill |
|
| November 2, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 02, 2023 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) - Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporatio |
|
| October 31, 2023 |
SC 13G 1 colcap13g102023.txt SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Helius Medical Technologies, Inc. - (Name of Issuer) Common Stock - (Title of Class of Securities) 42328V801 - (CUSIP Number) October 23, 2023 - (Date of Event which Requires Filing of this Statement) Check the ap |
|
| September 28, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 28, 2023 Date of Report (Date of earliest event reported) Helius Medical Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporation |
|
| September 28, 2023 |
Exhibit 99.1 Helius Medical Technologies, Inc. Receives UPC Numbers for its PoNS® System and Mouthpiece - UPC numbers assigned by Wolters Kluwer Health, provider of trusted clinical technology - - PoNS system and mouthpiece will be included in pharmacy database utilized by 17 out 20 of the top-grossing pharmacy benefit managers (PBMs) –- - PoNS expected to be one of few products with both pharmacy |
|
| September 11, 2023 |
HSDT / Helius Medical Technologies Inc - Class A / ANDREEFF DANE - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. |
|
| September 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 05, 2023 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) - Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporati |
|
| September 5, 2023 |
Helius Medical Technologies, Inc. Compliant with All Applicable Nasdaq Listing Criteria Exhibit 99.1 Helius Medical Technologies, Inc. Compliant with All Applicable Nasdaq Listing Criteria NEWTOWN, Pa., September 5, 2023 – Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that on August 31, 2023, Helius received formal notice |
|
| August 16, 2023 |
Helius Medical Technologies Announces Reverse Stock Split Exhibit 99.1 Helius Medical Technologies Announces Reverse Stock Split NEWTOWN, Pa., August 16, 2023 (GLOBE NEWSWIRE) - Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, announced today a 1-for-50 reverse split of its Class A common stock, par value $0.00 |
|
| August 16, 2023 |
Exhibit 3.1 CORRECTED CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF HELIUS MEDICAL TECHNOLOGIES, INC. Helius Medical Technologies, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), certifies that: 1. The Certificate of Amendment to the Certificate of Incorporation that was filed with the Delaware Secretary of State |
